Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SLS vs LCTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LCTX Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

LCTX Overall Winner 6-Pillar Tally: SLS 1 – 4 LCTX (1 Tie) Matrix Metrics: SLS 3 – 7 LCTX

As of Nov 20, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over SELLAS Life Sciences Group, Inc. (SLS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SLS carries a Unified Composite Score of 33.6/100 (SELL) at $13.66 (N/M Forward P/E, 0.0% operating margin), whereas LCTX carries 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin).

  • Technical & Structure Timing Caution: SLS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.5); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SLS vs LCTX
SLS NASDAQ
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$13.66
-8.08% 1D
Market Cap $3.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.91β · 550% Vol
Unified Composite Score
33.6 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 48.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 56
RSI-14: 56.5 · SMA20: $10.55 · SMA50: $11.16
LCTX NYSE American Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.39β · 79% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $0.97 · SMA50: $0.97

6-Pillar Scorecard Institutional Category Breakdown (SLS 1 – 4 LCTX)

Columns: Metric · SLS · LCTX
1. Valuation Multiples LCTX
Forward P/E N/M 30.7x
Trailing P/E N/M 30.7x
PEG Ratio N/M 10.64x
EV / Revenue N/M 15.9x
2. Growth & Scale LCTX
Revenue Growth (YoY) -82.5% -61.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $11M
Market Cap $3.0B $207.4M
3. Profitability & Quality LCTX
Gross Margin N/A -95.0%
Operating Margin 0.0% -280.3%
Net Profit Margin 0.0% 16.2%
Return on Equity (ROE) -40.3% 4.3%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$28M -$24M
Cash Flow Margin N/A N/A
Net Cash / Leverage $138M Net Cash $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SLS
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 109.5% (5th %ile) 0.0% (<1st %ile)
Put/Call OI Skew 0.45x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SLS (3) vs LCTX (7)
Institutional Metric SLS LCTX Criterion Row Edge
Market Capitalization
Scale
$3.0B $207.4M Larger Scale SLS
Trailing P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-82.5% -61.0% Higher Growth LCTX
Operating Margin (TTM)
Profitability
0.0% -280.3% Higher Margin SLS
Net Profit Margin
Profitability
0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
-40.3% 4.3% Higher ROE LCTX
52-Week Range Position
Momentum
52% ($1–$25) 0% ($1–$2) Stronger Trend SLS
Beta / 30D Volatility
Risk Regime
1.91β · 550% Vol 1.39β · 79% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
33.6 / 100 (SELL) 54.9 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 10.64x PEG · 15.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M ($138M Net Cash) -$24M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLS +41.98 pp
SLS: +20.35% · LCTX: -21.63%
3M Horizon SLS +24.54 pp
SLS: -4.64% · LCTX: -29.18%
6M Horizon SLS +116.2 pp
SLS: +75.58% · LCTX: -40.62%
1Y Horizon SLS +853.54 pp
SLS: +798.68% · LCTX: -54.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SLS Revenue LCTX Revenue SLS Op. Margin LCTX Op. Margin Margin Leader
FY2018 N/A $0M N/A -837.9% LCTX
FY2019 N/A $0M N/A -1106.0% LCTX
FY2020 $0M $0M -893.8% -1448.4% SLS
FY2021 $10M $0M -332.8% -1133.6% SLS
FY2022 $0M $10M -4195.0% -153.2% LCTX
FY2023 N/A $10M N/A -276.5% LCTX
FY2024 N/A $10M N/A -226.1% LCTX
FY2025 N/A $10M N/A -251.6% LCTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SLS CONSOLIDATION
102d in phase · OBV ACCUMULATION
Current IV 109.5%
IV Percentile 5th %ile
Put/Call OI Skew 0.45x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
7d in phase · OBV DISTRIBUTION
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $19.15 · IV 151.5%

SLS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,915)

Compare $1,915 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 151.5% ATM IV.

5-DAY BULLISH SWING Liq B

Nov 27 $20 / $23 Bull Call Spread

Buy 2x $20C · Sell 2x $23C · 10d

Net Entry $176 Debit
T+5d @ +5% Move +$26 (+15%)
Max Risk / Buffer $176 Capped
5d Edge & Liquidity 0.4x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $17 / $15 Bull Put Spread

Sell 4x $17P · Buy 4x $15P · 59d

Net Entry $340 Credit
Max Credit / Yield +$340 (+73.9% RoM)
Max Risk / Buffer -15.7% Cushion ($460 Mgn)
5d Edge & Liquidity 69% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SLS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $207.4M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SLS vs LCTX Key Questions & Quantitative Answers

As of Nov 20, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over SELLAS Life Sciences Group, Inc. (SLS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SLS carries a Unified Composite Score of 33.6/100 (SELL) at $13.66 (N/M Forward P/E, 0.0% operating margin), whereas LCTX carries 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin). Technical & Structure Timing Caution: SLS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.5); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LCTX leads the Growth & Scale pillar: SLS posts -82.5% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SLS cumulative revenue shifted N/A while LCTX shifted +0.0%. In operating R&D and SG&A reinvestment, SLS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.

LCTX screens cheaper on headline valuation multiples. SLS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 15.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLS (-40.3% ROE) versus LCTX (4.3% ROE) capital efficiency.

In options market volatility and institutional positioning, SLS carries 109.5% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 550% Vol realized risk). By comparison, LCTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.